Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022
[170 Pages Report] The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics
Market Dynamics
Increasing global prevalence of infectious diseases
The global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV, and tuberculosis is considerably high in spite of significant improvements in sanitation practices and medicine. Many of the currently available diagnostic techniques are slow, involve complex procedures, and lack specific identification of causative agents. Owing to this, patients receive empiric, broad-spectrum antimicrobial therapy rather than appropriate therapies. This has resulted in the emergence of super-resistant microbes
Inadequate reimbursements
According to MedPAC (Medicare Payment Advisory Commission), medical testing has witnessed a 40% decline in reimbursements over the past 40 years. Budgetary considerations among healthcare systems act as a major obstacle for the implementation of novel diagnostic techniques in clinical laboratories as reimbursements for these tests are low.
Medicare revised its reimbursement mechanism for some IVD tests, including infectious disease molecular tests, in 2012. Some of these molecular pathology tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are instead billed using unlisted codes. In the case of these codes, Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions.
According to CMS, 75% tests will show reimbursement rate reductions under the proposed 2018 Medicare payment rate. Some of these tests include molecular tests, targeted next-generation sequencing analysis, panels of 5 to 50 genes, and cancer tests.
These reduced reimbursements are expected to adversely affect the adoption of molecular and genetic testing in the US, which will, in turn, hinder the growth of the market.
Growing awareness about personalized medicine
Growing patient awareness about the benefits of personalized medicine is one of the key factors resulting in the increased use of molecular diagnostics and genomics & proteomics technologies in infectious disease testing. Diagnostic tests can be used to assess the efficacy of specific therapeutic agents in particular patients. With the help of diagnostic tests, patients who suffer disproportionately severe adverse effects from a given treatment or dosage can be identified. Moreover, diagnostic tests help in determining the optimal dosages for drugs whose therapeutic effects are known to vary widely among different patient groups. The extent or progression of a disease and preventive measures can be identified in patients through diagnostic tests. With the growing demand for personalized medicine, the demand for such diagnostic tests is expected to increase globally.
One of the most widely used personalized treatment regimens includes therapeutic drug monitoring tests to select drugs for resistant HIV strains. According to a Los Angeles Times article, in a March 2012 survey conducted by the United Health Center for Health Reform & Modernization, more than 75% respondents agreed that genetic testing allowed physicians to offer personalized treatment. The survey also stated that the US annually spends USD 5 billion on genetic tests, which could reach USD 1525 billion by 2021. The growing availability of genetic and molecular diagnostic tests plays a crucial role in enabling the early detection of diseases and providing more personalized treatments; this can potentially result in substantial savings in treatment costs.
Objectives of the Study
- To define, describe, and segment the global infectious disease diagnostics (IDD) market by product & service, technology, disease type, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, and opportunities)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the global market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players
- To forecast the size of the global infectious disease diagnostics industry segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)
- To profile the key players in the market and comprehensively analyze their market positions and core competencies
- To track and analyze competitive developments such as acquisitions, product launches and approvals, expansions, and other developments in the market
Research Methodology
Both, top-down and bottom-up approaches were used to validate the size of the global infectious disease diagnostics market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research and their market presence was studied through primary and secondary research. Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases. Whereas, primary research included extensive interviews with key opinion leaders such as CEOs, vice presidents, directors, marketing executives, and related key executives from various companies. The percentage splits, shares, and breakdowns of the segments were determined using secondary sources and verified through primary sources. This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.
To know about the assumptions considered for the study, download the pdf brochure
The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), bioMerieux (France), Bio-Rad (US), and Roche (Switzerland).
Target Audience:
- Infectious Disease Diagnostic Manufacturers
- Physicians
- Academic Institutes
- Research Institutes
- Reference Laboratories
- Diagnostics Suppliers
- Blood Banks
- Home Health Agencies
- Market Research and Consulting Firms
- Regulatory Bodies
- Venture Capitalists
Scope of the Report
The research report categorizes the global market into the following segments and subsegments:
- Assays, Kits, & Reagents
- Instruments
- Services and Software
- Hepatitis
- HIV
- CT/NG
- HAIs
- HPV
- TB
- Influenza
- Other Diseases
- Immunodiagnostics
- Clinical Microbiology
- PCR
- INAAT
- DNA Sequencing & NGS
- DNA Microarrays
- Other Technologies
- Hospitals/Clinical Laboratories
- Reference Laboratories
- Physician Offices
- Academic/Research Institutes
- Other End Users
- North America
- US
- Canada
- Europe
- Asia Pacific
- Rest of the World (RoW)
Market, by Product & Service
Market, by Disease Type
Market, by Technology
Market, by End User
Market, by Region
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Product Analysis
Product matrix, which gives a detailed comparison of the product portfolios of each company
Company Information
Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
Detailed analysis of infectious disease diagnostics market in European countries such as the UK, Germany, France, Italy, Spain, and others
Detailed analysis of market in Asia Pacific countries such as China, Japan, India, and others
The global infectious disease diagnostics market is projected to reach USD 19.35 Billion in 2022 from USD 14.73 Billion in 2017, at CAGR of 5.6%. Infectious disease diagnostics are various techniques used by healthcare professionals to detect and diagnose diseases causing pathogens in human samples such as serum, blood, urine, throat swab, and stool. Growth in this market is largely be driven by the increasing global prevalence of infectious diseases, the shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.
In this report, the market has been categorized based on product & service, disease type, technology, end user, and region.
The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service. The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.
Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases. The hepatitis diagnostics segment accounted for the largest share of the global market in 2017. The dominant share of this segment can be attributed to the rising prevalence of hepatitis B and C, the availability of a large number of hepatitis diagnostic tests, and increasing number of HIV/Hepatitis co-infections.
The infectious disease diagnostics market is segmented into major seven technologies, namely, immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and other technologies. In 2017, the immunodiagnostics segment accounted for the largest share of the global market. The large share of this segment can be attributed to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, and increasing awareness about health and fitness.
On the basis of end user, the global market is segmented into hospitals/clinical laboratories, reference laboratories, physician offices, academic/research institutes, and other end users. In 2017, the hospitals/clinical laboratories segment accounted for the largest share of the global market. Also, this segment is expected to grow at the highest CAGR during the forecast period due to the large number of diagnostic tests carried out in hospitals.
In 2017, in terms of value, North America accounted for the largest share of the global market. This large share can be attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
However, inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques are restraining market growth.
The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), biomιrieux (France), Bio-Rad (US), and Roche (Switzerland). These players focus on inorganic strategies such as acquisitions, partnerships, agreements, collaborations and as well as organic strategies such as expansions and product launches & approvals to sustain their growth in the market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 15)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology (Page No. - 18)
2.1 Primary Data
2.1.1 Key Data From Primary Sources
2.1.2 Key Industry Insights
2.2 Secondary Data
2.2.1 Key Data From Secondary Sources
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.4.1 Assumptions for the Study
3 Executive Summary (Page No. - 26)
4 Premium Insights (Page No. - 30)
4.1 Infectious Disease Diagnostics: Market Overview
4.2 Infectious Disease Diagnostics Market, By Technology and Region (2017)
4.3 Market, By Product & Service, 2017 vs 2022 (USD Billion)
4.4 Market, By End User
5 Market Overview (Page No. - 33)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Global Prevalence of Infectious Diseases
5.2.1.2 Shift in Focus From Centralized Laboratories to Decentralized Point-Of-Care Testing
5.2.1.3 Growth in Funding for Research on Infectious Disease Diagnostics
5.2.2 Restraints
5.2.2.1 Inadequate Reimbursements
5.2.2.2 Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
5.2.3 Opportunities
5.2.3.1 Advances in Genomics and Proteomics
5.2.3.2 Growing Awareness About Personalized Medicine
5.2.3.3 Growth Opportunities in Emerging Markets
6 Infectious Disease Diagnostics Market, By Product & Service (Page No. - 38)
6.1 Introduction
6.2 Assays, Kits, & Reagents
6.3 Instruments
6.4 Services & Software
7 Infectious Disease Diagnostics Market, By Technology (Page No. - 44)
7.1 Introduction
7.1.1 Immunodiagnostics
7.1.2 Clinical Microbiology
7.1.3 Polymerase Chain Reaction (PCR)
7.1.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.1.5 DNA Sequencing & Next-Generation Sequencing (NGS)
7.1.6 DNA Microarray
7.1.7 Other Technologies
8 Infectious Disease Diagnostics Market, By Disease Type (Page No. - 55)
8.1 Introduction
8.1.1 Hepatitis
8.1.1.1 Hepatitis Diagnostics Market, By Technology
8.1.2 Human Immunodeficiency Virus (HIV)
8.1.3 Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
8.1.4 Hospital-Acquired Infections (HAIS)
8.1.5 Human Papillomavirus (HPV)
8.1.6 Tuberculosis (TB)
8.1.6.1 Tuberculosis Diagnostics Market, By Technology
8.1.7 Influenza
8.1.7.1 Influenza Diagnostics Market, By Technology
8.1.8 Other Infectious Diseases
9 Infectious Disease Diagnostics Market, By End User (Page No. - 68)
9.1 Introduction
9.2 Hospital/Clinical Laboratories
9.3 Reference Laboratories
9.4 Physician Offices
9.5 Academic/Research Institutes
9.6 Other End Users
10 Infectious Disease Diagnostics Market, By Region (Page No. - 76)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.4 Asia Pacific (APAC)
10.5 Rest of the World (RoW)
11 Competitive Landscape (Page No. - 98)
11.1 Market Overview
11.2 Market Ranking Analysis, 2017
11.3 Competitive Situation and Trends
11.3.1 Product Launches and Approvals
11.3.2 Collaborations, Agreements, and Partnerships
11.3.3 Acquisitions
11.3.4 Expansions
12 Company Profiles (Page No. - 104)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Abbott Laboratories
12.2 Becton, Dickinson and Company
12.3 Biomιrieux SA
12.4 Bio-Rad Laboratories
12.5 Danaher Corporation
12.6 Diasorin
12.7 Luminex
12.8 Meridian Bioscience
12.9 Quidel
12.10 Roche Diagnostics
12.11 Siemens AG
12.12 Thermo Fisher Scientific
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 161)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets Subscription Portal
13.3 Introducing RT: Real-Time Market Intelligence
13.4 Available Customizations
13.5 Related Reports
13.6 Author Details
List of Tables (85 Tables)
Table 1 New Tests Launched By Key Players
Table 2 Infectious Disease Diagnostics Market, By Product & Service, 20152022 (USD Million)
Table 3 Infectious Disease Diagnostic Assays, Kits, & Reagents Market, By Region, 20152022 (USD Million)
Table 4 North America: Infectious Disease Diagnostic Assays, Kits, & Reagents Market, By Country, 20152022 (USD Million)
Table 5 Infectious Disease Diagnostic Instruments Market, By Region, 20152022 (USD Million)
Table 6 North America: Infectious Disease Diagnostic Instruments Market, By Country, 20152022 (USD Million)
Table 7 Infectious Disease Diagnostic Services & Software Market, By Region, 20152022 (USD Million)
Table 8 North America: Infectious Disease Diagnostic Services & Software Market, By Country, 20152022 (USD Million)
Table 9 Infectious Diseases Diagnostics Market, By Technology, 20152022 (USD Million)
Table 10 Market for Immunodiagnostics, By Region, 20152022 (USD Million)
Table 11 North America: Market for Immunodiagnostics, By Country, 20152022 (USD Million)
Table 12 Market for Clinical Microbiology, By Region, 20152022 (USD Million)
Table 13 North America: Market for Clinical Microbiology, By Country, 20152022 (USD Million)
Table 14 Market for PCR, By Region, 20152022 (USD Million)
Table 15 North America: Market for PCR, By Country, 20152022 (USD Million)
Table 16 Infectious Disease Diagnostics Market for INAAT, By Region, 20152022 (USD Million)
Table 17 North America: Market for INAAT, By Country, 20152022 (USD Million)
Table 18 DNA Sequencing & NGS Market, By Region, 20152022 (USD Million)
Table 19 North America: DNA Sequencing & NGS Market, By Country, 20152022 (USD Million)
Table 20 Market for DNA Microarray, By Region, 20152022 (USD Million)
Table 21 North America: Market for DNA Microarray, By Country, 20152022 (USD Million)
Table 22 Market for Other Technologies, By Region, 20152022 (USD Million)
Table 23 North America: Market for Other Technologies, By Country, 20152022 (USD Million)
Table 24 Infectious Diseases Diagnostics Market, By Disease Type, 20152022 (USD Million)
Table 25 Hepatitis Diagnostics Market, By Region, 20152022 (USD Million)
Table 26 North America: Hepatitis Diagnostics Market, By Country, 20152022 (USD Million)
Table 27 Hepatitis Diagnostics Market, By Technology, 20152022 (USD Million)
Table 28 HIV Diagnostics Market, By Region, 20152022 (USD Million)
Table 29 North America: HIV Diagnostics Market, By Country, 20152022 (USD Million)
Table 30 CT/NG Diagnostics Market, By Region, 20152022 (USD Million)
Table 31 North America: CT/NG Diagnostics Market, By Country, 20152022 (USD Million)
Table 32 Hai Diagnostics Market, By Region, 20152022 (USD Million)
Table 33 North America: Hai Diagnostics Market, By Country, 20152022 (USD Million)
Table 34 HPV Diagnostics Market, By Region, 20152022 (USD Million)
Table 35 North America: HPV Diagnostics Market, By Country, 20152022 (USD Million)
Table 36 Tuberculosis Diagnostics Market, By Region, 20152022 (USD Million)
Table 37 North America: Tuberculosis Diagnostics Market, By Country, 20152022 (USD Million)
Table 38 Tuberculosis Diagnostics Market, By Technology, 20152022 (USD Million)
Table 39 Influenza Diagnostics Market, By Region, 20152022 (USD Million)
Table 40 North America: Influenza Diagnostics Market, By Country, 20152022 (USD Million)
Table 41 Influenza Diagnostics Market, By Technology, 20152022 (USD Million)
Table 42 Other Infectious Disease Diagnostics Market, By Region, 20152022 (USD Million)
Table 43 North America: Other Market, By Country, 20152022 (USD Million)
Table 44 Market Size, By End User, 20152022 (USD Million)
Table 45 Market for Hospital/Clinical Laboratories, By Region, 20152022 (USD Million)
Table 46 North America: Market for Hospital/Clinical Laboratories, By Country, 20152022 (USD Million)
Table 47 Market for Reference Laboratories, By Region, 20152022 (USD Million)
Table 48 North America: Market for Reference Laboratories, By Country, 20152022 (USD Million)
Table 49 Market for Physician Offices, By Region, 20152022 (USD Million)
Table 50 North America: Market for Physician Offices, By Country, 20152022 (USD Million)
Table 51 Market for Academic/Research Institutes, By Region, 20152022 (USD Million)
Table 52 North America: Market for Academic/Research Institutes, By Country, 20152022 (USD Million)
Table 53 Market for Other End Users, By Region, 20152022 (USD Million)
Table 54 North America: Market for Other End Users, By Country, 20152022 (USD Million)
Table 55 Infectious Disease Diagnostics Market, By Region, 20152022 (USD Million)
Table 56 North America: Market, By Country, 20152022 (USD Million)
Table 57 North America: Market, By Product & Service, 20152022 (USD Million)
Table 58 North America: Market, By Technology, 20152022 (USD Million)
Table 59 North America: Market, By Disease Type, 20152022 (USD Million)
Table 60 North America: Market, By End User, 20152022 (USD Million)
Table 61 US: Market, By Product & Service, 20152022 (USD Million)
Table 62 US: Market, By Technology, 20152022 (USD Million)
Table 63 US: Market, By Disease Type, 20152022 (USD Million)
Table 64 US: Market, By End User, 20152022 (USD Million)
Table 65 Canada: Market, By Product & Service, 20152022 (USD Million)
Table 66 Canada: Market, By Technology, 20152022 (USD Million)
Table 67 Canada: Market, By Disease Type, 20152022 (USD Million)
Table 68 Canada: Market, By End User, 20152022 (USD Million)
Table 69 Europe: Market, By Product & Service, 20152022 (USD Million)
Table 70 Europe: Market, By Technology, 20152022 (USD Million)
Table 71 Europe: Market, By Disease Type, 20152022 (USD Million)
Table 72 Europe: Market, By End User, 20152022 (USD Million)
Table 73 APAC: Infectious Disease Diagnostics Market, By Product & Service, 20152022 (USD Million)
Table 74 APAC: Market, By Technology, 20152022 (USD Million)
Table 75 APAC: Market, By Disease Type, 20152022 (USD Million)
Table 76 APAC: Market, By End User, 20152022 (USD Million)
Table 77 RoW: Market, By Product & Service, 20152022 (USD Million)
Table 78 RoW: Market, By Technology, 20152022 (USD Million)
Table 79 RoW: Market, By Disease Type, 20152022 (USD Million)
Table 80 RoW: Market, By End User, 20152022 (USD Million)
Table 81 Rank of Companies in the Global Market, 2017
Table 82 Product Launches, 2015-2018
Table 83 Collaborations, Partnerships, and Agreements, 2015 & 2018
Table 84 Acquisitions, 2015-2017
Table 85 Expansions, 2015 to 2017
List of Figures (35 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Market, By Product & Service, 2017 vs 2022
Figure 7 Market, By Disease Type, 2017 vs 2022
Figure 8 Market, By Technology, 2017 vs 2022
Figure 9 Market, By End User, 2017 vs 2022
Figure 10 Geographical Snapshot of the Market
Figure 11 Increasing Prevalence of Infectious Diseases is A Key Driver for the Market
Figure 12 Immunodiagnostics Technology Segment Accounted for the Largest Share of the Market in 2017
Figure 13 Assays, Kits & Reagents Will Continue to Dominate the Infectious Disease Diagnostics Market in 2022
Figure 14 Hospitals & Clinical Laboratories Accounted for the Largest Market Share in 2017
Figure 15 Market: Drivers, Restraints, and Opportunities
Figure 16 Assays, Kits, & Reagents to Witness the Highest Growth During the Forecast Period
Figure 17 Immunodiagnostics to Dominate the IDD Market During the Forecast Period (20172022)
Figure 18 Hepatitis Disease Diagnostics Segment to Dominate the IDD Market During the Forecast Period (20172022)
Figure 19 Market Size, By End User, 2017-2022 (USD Million)
Figure 20 Geographical Snapshot: Asia Pacific to Be the Fastest-Growing Regional Segment in the Market
Figure 21 North America: Market Snapshot
Figure 22 Asia Pacific: Market Snapshot
Figure 23 Key Developments in the Market Between 2013 and 2016
Figure 24 Abbott Laboratories: Company Snapshot (2016)
Figure 25 Becton, Dickinson and Company: Company Snapshot (2017)
Figure 26 Biomιrieux Sa: Company Snapshot (2016)
Figure 27 Bio-Rad Laboratories: Company Snapshot (2016)
Figure 28 Danaher Corporation: Company Snapshot (2016)
Figure 29 Diasorin: Company Snapshot (2017)
Figure 30 Luminex: Company Snapshot (2016)
Figure 31 Meridian Bioscience: Company Snapshot (2017)
Figure 32 Quidel: Company Snapshot (2016)
Figure 33 Roche Diagnostics: Company Snapshot (2017)
Figure 34 Siemens AG: Company Snapshot (2017)
Figure 35 Thermo Fisher Scientific: Company Snapshot (2016)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Infectious Disease Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Infectious Disease Diagnostics Market